Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.
Exp Mol Med. 2021 Mar;53(3):446-456. doi: 10.1038/s12276-021-00583-1. Epub 2021 Mar 22.
The global incidence of early-onset colorectal cancer (EO-CRC) is rapidly rising. However, the reason for this rise in incidence as well as the genomic characteristics of EO-CRC remain largely unknown. We performed whole-exome sequencing in 47 cases of EO-CRC and targeted deep sequencing in 833 cases of CRC. Mutational profiles of EO-CRC were compared with previously published large-scale studies. EO-CRC and The Cancer Genome Atlas (TCGA) data were further investigated according to copy number profiles and mutation timing. We classified colorectal cancer into three subgroups: the hypermutated group consisted of mutations in POLE and mismatch repair genes; the whole-genome doubling group had early functional loss of TP53 that led to whole-genome doubling and focal oncogene amplification; the genome-stable group had mutations in APC and KRAS, similar to conventional colon cancer. Among non-hypermutated samples, whole-genome doubling was more prevalent in early-onset than in late-onset disease (54% vs 38%, Fisher's exact P = 0.04). More than half of non-hypermutated EO-CRC cases involved early TP53 mutation and whole-genome doubling, which led to notable differences in mutation frequencies between age groups. Alternative carcinogenesis involving genomic instability via loss of TP53 may be related to the rise in EO-CRC.
早发性结直肠癌(EO-CRC)的全球发病率正在迅速上升。然而,发病率上升的原因以及 EO-CRC 的基因组特征在很大程度上仍不清楚。我们对 47 例 EO-CRC 病例进行了全外显子组测序,并对 833 例 CRC 病例进行了靶向深度测序。将 EO-CRC 的突变谱与之前发表的大规模研究进行了比较。根据拷贝数谱和突变时间进一步研究了 EO-CRC 和癌症基因组图谱(TCGA)数据。我们将结直肠癌分为三组:高度突变组包括 POLE 和错配修复基因突变;全基因组倍增组具有早期功能丧失的 TP53,导致全基因组倍增和局灶性癌基因扩增;基因组稳定组具有 APC 和 KRAS 突变,类似于传统结肠癌。在非高度突变样本中,早发性疾病中全基因组倍增比晚发性疾病更为常见(54%比 38%,Fisher 精确检验 P=0.04)。超过一半的非高度突变 EO-CRC 病例涉及早期 TP53 突变和全基因组倍增,这导致了不同年龄组之间突变频率的显著差异。涉及 TP53 丢失的基因组不稳定性的替代致癌作用可能与 EO-CRC 的上升有关。
Carcinogenesis. 2018-12-13
Virchows Arch. 2016-8
World J Gastroenterol. 2013-8-28
Pathol Res Pract. 2019-7-27
Front Genet. 2025-5-30
PLoS Comput Biol. 2025-4-3
Medicina (Kaunas). 2025-2-26
Biomolecules. 2025-2-8
Signal Transduct Target Ther. 2024-6-19
Nature. 2019-10-23
Clin Cancer Res. 2019-6-26
Am J Gastroenterol. 2019-2
Science. 2018-10-18
Nat Genet. 2018-9-17
Nat Genet. 2018-7-16